[go: up one dir, main page]

MX2018006445A - Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. - Google Patents

Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos.

Info

Publication number
MX2018006445A
MX2018006445A MX2018006445A MX2018006445A MX2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A
Authority
MX
Mexico
Prior art keywords
methods
fibrosis
disclosed
same
antisense oligonucleotide
Prior art date
Application number
MX2018006445A
Other languages
English (en)
Inventor
Francesca Viti
Salvatore Bellinvia
MCNULTY Marie
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX2018006445A publication Critical patent/MX2018006445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aquí se describen secuencias de oligonucleótidos antisentido contra IL-34 y métodos para tratar enfermedades inflamatorias, tales como enfermedad inflamatoria del intestino, y/o fibrosis, asociadas con actividad elevada o expresión de IL-34; también se describen composiciones farmacéuticas que contienen un oligonucleótido antisentido de IL-34 útil para tratar enfermedades inflamatorias y/o fibrosis y fabricación de medicamentos que contienen un oligonucleótido antisentido de IL-34 descrito para usar en el tratamiento de enfermedades inflamatorias y/o fibrosis.
MX2018006445A 2015-11-25 2016-11-25 Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. MX2018006445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260076P 2015-11-25 2015-11-25
PCT/EP2016/078833 WO2017089555A1 (en) 2015-11-25 2016-11-25 Il-34 antisense oligonucleotides and methods of using same

Publications (1)

Publication Number Publication Date
MX2018006445A true MX2018006445A (es) 2018-08-01

Family

ID=57471829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006445A MX2018006445A (es) 2015-11-25 2016-11-25 Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos.

Country Status (13)

Country Link
US (1) US20180338992A1 (es)
EP (1) EP3380615B1 (es)
JP (2) JP2018535681A (es)
KR (1) KR20180084956A (es)
CN (1) CN108473989A (es)
AU (1) AU2016360956A1 (es)
BR (1) BR112018010736A2 (es)
CA (1) CA3005932A1 (es)
ES (1) ES2861516T3 (es)
MA (1) MA44309A (es)
MX (1) MX2018006445A (es)
PT (1) PT3380615T (es)
WO (1) WO2017089555A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505598A (ja) * 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
BR112022009254A2 (pt) * 2019-11-15 2022-10-04 Nogra Pharma Ltd Agentes antissenso il-34 e métodos de usar os mesmos
KR20240009973A (ko) 2021-05-17 2024-01-23 노그라 파마 리미티드 Il-34 안티센스 작용제 및 이의 사용 방법
WO2022243299A1 (en) * 2021-05-17 2022-11-24 Nogra Pharma Limited Il-34 antisense agents and methods of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2242854A4 (en) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc COMPOUNDS AND USES THEREOF
CN107007616A (zh) 2008-11-13 2017-08-04 诺格拉制药有限公司 反义组合物及其制备和使用方法
GB0910833D0 (en) * 2009-06-23 2009-08-05 Univ Edinburgh Avian genes
CA2824843A1 (en) * 2010-02-04 2011-08-11 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
ES2618828T3 (es) * 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
WO2014036357A1 (en) * 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
KR20150104275A (ko) * 2014-03-05 2015-09-15 울산대학교 산학협력단 비만 관련 질환의 진단과 치료를 위한 il-34의 용도
ES3047792T3 (en) * 2014-07-14 2025-12-04 Univ California Crispr/cas transcriptional modulation

Also Published As

Publication number Publication date
EP3380615A1 (en) 2018-10-03
JP2021106625A (ja) 2021-07-29
CA3005932A1 (en) 2017-06-01
KR20180084956A (ko) 2018-07-25
US20180338992A1 (en) 2018-11-29
MA44309A (fr) 2018-10-03
AU2016360956A1 (en) 2018-06-07
PT3380615T (pt) 2021-04-01
BR112018010736A2 (pt) 2018-11-27
EP3380615B1 (en) 2021-01-06
JP2018535681A (ja) 2018-12-06
CN108473989A (zh) 2018-08-31
ES2861516T3 (es) 2021-10-06
WO2017089555A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
IL284423A (en) Antisense oligonucleotides for the treatment of Pompe disease
NZ730296A (en) Modified double-stranded rna agents
PH12018500719A1 (en) Oligonucleotide compositions and methods thereof
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MY182095A (en) Autotaxin inhibitor compounds
PH12017500424A1 (en) Mir-29 mimics and uses thereof
MX359548B (es) Agentes de iarn modificados.
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
EP3128008C0 (en) DOUBLE-STRANDED OLIG-RNA AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR THE PREVENTION OR TREATMENT OF FIBROSIS OR RESPIRATORY DISEASES
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
HK1252852A1 (zh) 阻止HIF2α基因表达的组合物及方法
MX2016006688A (es) Inhibidores tetraciclicos de autotaxina.
TW201613949A (en) Targeting microRNAs for metabolic disorders
MX2018006445A (es) Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2018005872A (es) Profarmacos de acido nucleico.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
MX2022005900A (es) Agentes antisentido de il-34 y metodos de uso de los mismos.
HK1202868A1 (en) Carboxamide-substituted heteroaryl-pyrazoles and the use thereof
MX368084B (es) siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR.